Skip to search formSkip to main contentSkip to account menu

CUDC 101

Known as: CUDC-101, CUDC101 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
CUDC-101 Overcomes Arsenic Trioxide Resistance Via Caspase-Dependent PML-Rarα Degradation in Acute Promyelocytic Leukemia
While arsenic trioxide (ATO) treatment has transformed acute promyelocytic leukemia (APL) from the most fatal to the most curable… 
2017
2017
Abstract 2061: Non-covalent EGFR T790M targeting TKIs inhibit AZD9291 resistant EGFR C797S mutants
Approximately 10-15% of non-small-cell lung cancers (NSCLC) have epidermal growth factor receptor (EGFR) mutations resulting in… 
2014
2014
Cancer Therapy : Clinical Phase I First-inHuman Study of CUDC-101 , a Multitargeted Inhibitor of HDACs , EGFR , and HER 2 in Patients with Advanced Solid Tumors
Purpose: This first-in-human phase I study evaluated dose-limiting toxicities (DLT) and defined a phase II recommended dose (RD… 
2012
2012
Multi-targeted hybrids based on HDAC inhibitors for anti-cancer drug discovery
Multi-targeted hybrids combine two drugs in a single molecule to have greater medicinal effects than its individual components… 
2012
2012
CPI-613, AN INVESTIGATIONAL NOVEL ANTI-CANCER AGENT, PROVIDES LONG-TERM STABLE DISEASE WITHOUT SIGNIFICANT ADVERSE EFFECTS IN A PATIENT WITH STAGE IV RELAPSED HEPATOCELLULAR CARCINOMA
The current case study describes the safety and prolonged therapeutic effect of an investigational drug (CPI-613) in a patient… 
2012
2012
590 Final Results of a Phase Ib Study of CUDC-101, a Multitargeted Inhibitor of EGFR, HER2, and HDAC, in Patients with Advanced Head and Neck, Gastric, Breast, Liver, and Non-small Cell Lung Cancer
2011
2011
Abstract A39: Measurement of CUDC-101 target inhibition in circulating tumor cells using a fluorescent-based quantitative assay.
Introduction: The occurrence of receptor signaling redundancy in multiple cancer pathways has led to the growing development of… 
2011
2011
Abstract 2619: Potential advantages of CUDC-101, a multi-targeted HDAC, EGFR and HER2 inhibitor, on preventing drug resistance and tumor metastasis
CUDC-101 is a novel small-molecule multi-target anti-cancer agent currently in Phase Ib clinical trial, which targets histone… 
2010
2010
364 The first-in-human, first-in-class study of CUDC-101, a multi-targeted inhibitor of HDAC, EGFR, and HER2: A Phase I study in patients with advanced cancer
2007
2007
CUDC-101, a synthetic and potent HDAC, EGFR and Her2 inhibitor, effectively inhibits proliferation of cancer cell lines
B275 HDAC and receptor tyrosine kinases have emerged as validated cancer targets. We first demonstrated that the epigenetic… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)